recombinant human LFA-3/antibody fusion protein (Taizhou Mabtech Pharmaceutical/Shanghai Zj Bio-Tech)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namerecombinant human LFA-3/antibody fusion protein (Taizhou Mabtech Pharmaceutical/Shanghai Zj Bio-Tech)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionT-cell surface antigen CD2 inhibitors
TargetsT-cell surface antigen CD2
Therapy Area/IndicationsPsoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Clinical)
Highest Status in ChinaPending
Originator CompaniesTaizhou Mabtech Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTaizhou Mabtech Pharmaceutical Co LtdShanghai Zhangjiang Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A